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Hypertension is one of the most common medical conditions, affecting nearly one-third of 
Americans.1 Chronic high blood pressure is the cause of numerous cardiovascular diseases which 
cost the United States over $100 billion annually.1 The American College of Cardiology and 
American Heart Association have recently challenged the previous definition of hypertension by 
suggesting those with a blood pressure of ≥130/80 mmHg now have the disease.2 This new 
threshold would classify nearly 50% of Americans as hypertensive.2 Establishing a diagnosis of 
hypertension can be difficult and resource intensive requiring patients to have serial recordings 
over 24-hours. Until recently there has been no reliable strategy for indexing the 24-hour 
ambulatory blood pressure in the clinic. This thesis used the Proof-BP algorithm along with 
traditional Clinic BP measurements to analyze MI, stroke, and CHF prevalence in hypertensive 
NHANES participants. Additionally, the sensitivity, specificity, and predictive values of Proof-
BP and Clinic BP were calculated. Based on the findings of this study, Proof-BP may be 
advantageous at assessing cardiovascular prevalence in certain groups. Due to its high specificity 
and negative predictive value, Proof-BP provides a reliable method of ruling out cardiovascular 
disease in healthy populations. Importantly, Proof-BP allows for detection of white coat 
hypertension and masked hypertension, both of which are impossible to detect from a single 
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Cardiovascular Outcomes in Hypertension as 
Defined by Proof-BP Using NHANES 2015-2016 
Kamran Javadi, Department of Chronic Disease Epidemiology, Yale School of Public Health 
 
Introduction 
Hypertension is the world’s most preventable cause of premature mortality.3 Costing the 
United States $131 billion annually, it affects one-third of American adults1 with this number 
increasing when looking at those over 60 years old.4 The guidelines for defining the disease have 
evolved over the years with hypertension defined in The Eighth Joint National Committee 
(JNC8) as greater than 140 mmHg systolic or greater than 90 mmHg diastolic.5 However, these 
guidelines were controversially challenged in 2017 with the American College of Cardiology 
(ACC) and American Heart Association (AHA) redefining hypertension as greater than 130 
mmHg systolic or greater than 80 mmHg diastolic.2, 5 Lowering the diagnostic threshold would 
reclassified an additional 31 million adults as hypertensive.6  This high amount of potential 
reclassification heightens the need for a simple clinical method to ensure proper identification of 
individuals who might be misclassified as having hypertension. In fact, this need has led to the 
creation of clinical tools, such as Proof-BP, that are gaining relevance as ways to more 
accurately and easily determine blood pressure than current standards. 
The World Health Organization, European Society of Cardiology, and the American 
Diabetes Association still maintain that hypertension is defined as at least 140/90 mmHg.2, 7 
Individuals who have blood pressure ≥140/90 mmHg are at greater risk for developing 
cardiovascular, renal, and cerebrovascular disease8, however 13 million adults with hypertension 
have never been diagnosed9, suggesting a lower threshold would pick up some of these 
individuals. Importantly, simply lowering the threshold would still miss some with masked 
6 
 
hypertension as these individuals are normotensive during office screenings. Untreated 
hypertensive patients, as defined by JNC 8 criteria, have a 40% increased risk of all-cause 
mortality compared to normotensive patients.10 However, hypertensive patients with treated and 
controlled blood pressure demonstrate no additional risk of death compared to normotensives.10  
Moreover, treating hypertension has been shown to decrease rates of heart and kidney disease, 
stroke, and all-cause mortality.8 Evidence that together supports the need for both identification 
and careful management of patients with hypertension.   
 Diagnosing hypertension has historically been difficult because the nature of blood pressure 
means it is quite labile over a 24-hour cycle. Normal fluctuations can be caused by many factors 
such as time of day, physical activity, stress level, temperature, and medications.11 Patients are 
normally screened for hypertension in the clinical setting. Ideally, those who screen positive are 
sent home with an ambulatory blood pressure monitoring (ABPM) device. ABPM is the current 
gold standard for establishing a diagnosis of hypertension as it has been shown to be a better 
predictor of cardiovascular mortality than clinic blood pressure.12 It requires the patient to take 
home a device that records dozens of blood pressure readings over 24 hours. The patient then 
must come back to the clinic to have the results analyzed, creating extra burden and cost for the 
patient. These follow-up appointments also create additional patient load for the clinicians 
responsible for these visits. Family medicine physicians see an average of 83 patients per week13 
so the possibility of reducing this number would mean more time for other patients with more 
complex health concerns. ABPM is the recommended method for diagnosing hypertension, as a 
single clinic reading can lead to miscategorized blood pressures. Additionally, ABPM has been 
shown to better predict all-cause and cardiovascular mortality compared to clinic-based blood 
pressure.12, 14, 15 For example, in a meta-analysis by Kakaletsis et al. the authors found that blood 
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pressure calculated by ABPM better predicts ischemic stroke than a single clinic measurement.16 
The ability to diagnose hypertension from a single clinical encounter would be ideal however, 
until recently there has been no reliable strategy for indexing the 24-hour ambulatory blood 
pressure in the clinic. 
For clinical purposes, blood pressure is staged into four categories: Normal (<120/<80 
mmHg), Elevated (120-129/<80 mmHg), Stage 1 (130-139/80-89 mmHg), and Stage 2 (at least 
140/90 mmHg).5 The overall stage is determined by the higher of either the systolic or diastolic 
stages. A diagnosis can be made using ABPM that shows a 24-hour average of at least 125/75 
mmHg, a daytime average of at least 130/80 mmHg, or a nighttime average of at least 110/65 
mmHg.17 Clinic blood pressure of 140/90 usually correlates with a daytime ABPM of 135/85.17 
Developed in 2016, Proof-BP was designed to replace cumbersome ABPM in the diagnosing 
of hypertension. Proof-BP is a linear regression model that indexes a patient’s true, or 
ambulatory, blood pressure using information from a single clinic visit, albeit with the 
requirement of multiple blood pressure measurements in addition to other factors 
(BMI/medications/cardiovascular disease/etc.).18 While ABPM is considered the current gold 
standard, it is often not practiced in the real-world as it is inconvenient to patients and some 
insurance companies do not reimburse for the extra time providers spend analyzing the data.3 As 
such, Proof-BP was developed with the goal of accurately predicting a patient’s ambulatory 
blood pressure without serial measurements over many hours. The authors found it is possible to 
predict a patient’s ambulatory blood pressure using only data from a single office visit. The tool 
has been shown to accurately classify blood pressure, when compared to ABPM, in 93% of 
patients within a primary care setting.18 However, to date there has been no epidemiological 
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comparison of CVD prevalence as indicated from a single clinic visit’s blood pressure, and that 
enriched by using the Proof-BP assessment. 
This thesis will use NHANES 2015-2016 data to compare the prevalence of three 
cardiovascular outcomes, myocardial infarction (MI), stroke, and congestive heart failure (CHF) 
between Proof-BP calculated blood pressure and blood pressure determined by a single reading 
taken in clinic. The objective is to evaluate the sensitivity, specificity, and predictive values of 
Proof-BP for MI, stroke, and CHF compared to a single blood pressure measurement. Each year 
nearly 1.6 million American’s are diagnosed with either an MI or stroke.19 Coronary artery 
disease (CAD), which is the basis behind the pathophysiology of MI, is accelerated in 
hypertensive individuals,20 and about 70% of first MIs can be at least partially attributed to 
hypertension.21 Similarly, it is known that the incidence of stroke is commensurate with systolic 
and diastolic pressures, and blood pressure control is the single most important risk factor for 
reducing the occurrence of both ischemic and hemorrhagic strokes.22 In regards to CHF, the 
AHA has most recently estimated there are 6.2 million cases in the United States.19 This figure is 
an increase from 5.1 million during their 2012 estimation.19 The Framingham Heart Study found 
the lifetime risk of CHF increased by 100% in those with blood pressure ≥160/100 mmHg 
compared to <140/90 mmHg.23 The high incidence as well as significant morbidity and mortality 
associated with these outcomes make them ideal to study. While Proof-BP has been shown to 
accurately estimate ambulatory blood pressure, to our knowledge, its sensitivity and specificity 
for cardiovascular outcomes has not been compared to that of a single blood pressure 
measurement. Additionally, this thesis shows basic demographic-type comparisons using a 
representative population, and this has also not been examined previously.  
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This thesis hopes to further address public health outcomes related to hypertension using data 
from a single clinic visit. For example, while CVD is associated with sustained hypertension, the 
link between CVD and other types of hypertension is less well studied. This thesis will also be 
exploring the association of MI, stroke, and CHF in individuals who display White Coat 
Hypertension (WCH) or Masked Hypertension (MH). WCH is defined as high in-clinic blood 
pressure but normal blood pressure outside of the clinic.3 Conversely, patients with MH are 
normotensive in-clinic but have elevated ambulatory blood pressure.3 Calculating Proof-BP for 
all individuals will allow us to classify those who exhibit WCH and MH. The clinical 
significance of untreated WCH is controversial but most believe it does increases one’s 
cardiovascular morbidity and mortality risk, albeit probably not as much as sustained 
hypertension.3, 24 However, it is believed that patients with MH are at about the same risk for 
developing a cardiovascular event compared to patients with sustained hypertension.25 In 
addition, patients with MH are at risk of progressing to sustained hypertension.17  
The current 2017 guidelines for hypertension represent a 10 mmHg decrease for both systolic 
and diastolic blood pressure measurements compared to previous recommendations.2 While this 
decrease is argued to help detect a greater number of patients who have a high-risk of developing 
a CV outcome, relying on a single clinic visit will more likely misclassify patients. In this thesis, 
the analyses will be performed using the systolic of both the JNC 8 definition of hypertension 
(140 mmHg) and the ACC/AHA definition (130 mmHg), with the intent of examining both the 
prevalence of hypertension and population characteristics, as well as how many additional events 
will be captured using the lower threshold. For example, it is believed that there is a doubling of 




Using a tool such as Proof-BP to risk stratify patients is expected to reduce the number of 
patients who are misdiagnosed and alleviates the inconvenience and cost of 24-hour monitors. If 
we can show that Proof-BP is a strong index for population level prediction of probability of CV 
disease outcomes, the next step of prospectively addressing this index for high risk populations 
and broad clinical utility could eventually replace how we use blood pressure in epidemiological 
studies as well as diagnose individual patients with hypertension.  
Methods 
Study Population 
NHANES data is a collection of nationally representative cross-sectional survey data that is 
gathered annually. Each year, around 5,000 children, adolescents, and adults from around the 
United States are interviewed about their demographics, health, diet, and lifestyle choices. A 
physical exam and laboratory tests are also performed to gather additional information on each 
participant. This information is made publicly available and is used to identify population trends. 
This data often becomes the basis for many governmental guidelines and policies that affect the 
nation’s health.27 
We used the NHANES basic clinical assessment in adults, including blood pressure both as 
the initial “clinical” and entire set of 3 blood pressure measurements recorded in the visit. These 
three standard blood pressure measurements were used to calculate the Proof-BP values. As seen 
in Figure 1, we included both male and female participants who were part of the 2015-2016 
NHANES cohort and who were between 55 and 79 years old at the time of interview. This age 
range was chosen because older adults have higher rates of cardiovascular disease. Using 
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participants who are between 55 and 79 years old places the prevalence of MI, stroke, and CHF 
around 6-8% in the sample. In the NHANES dataset participants who are 80 years or older are 
recorded as simply 80 years old, therefore an upper end cutoff of 79 was appropriate to enable 
description of age as a continuous variable. Participants with missing data that would not allow 
for an accurate calculation of their Proof-BP were also excluded.  
Participant characteristics such as demographics and cardiovascular risk factors were 
included because of their association with blood pressure and cardiovascular disease. The non-
modifiable risk factors that were included are age, sex, and race. The modifiable risk factors 
include education, smoking status, BMI, and medication usage.  
 
Sampling and Analysis 
As seen in Figure 1, the NHANES dataset was randomly split into two groups using 
Simple Random Sampling in SAS version 9.4. This split allowed for internal validation of the 
traditional clinic BP and Proof-BP measurement strategies that are otherwise co-linear. One 
group was sampled as the Clinic BP group where the first of three blood pressure measurements 
were used to determine their blood pressure. The other group was sampled as the Proof-BP group 
where the Proof-BP algorithm was used to calculate their blood pressure. No significant 
differences of the characteristics were detected at the 0.05 alpha level between the two groups. 
Including these characteristics allowed for the detection of their differences across the two 
groups. For this analysis only systolic blood pressure was considered when determining 
hypertensive status. This was due to the diastolic Proof-BP calculation requiring certain 
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variables, such as history of peripheral artery disease, that were not included in the NHANES 
dataset. Below is the algorithm for Proof-BP systolic blood pressure. NHANES data permitted 
this estimate of systolic ambulatory blood pressure because in the NHANES data collection 
blood pressure was taken for three consecutive blood pressure measurements. After the 
participant rested for 5 minutes, blood pressure was taken by a physician who was certified for 
blood pressure measurement using a standardized protocol.28 All three measurements were taken 
with the participant sitting, with the right arm, and there was a 30 second rest between 
measurements.28  
Proof-BP Systolic Blood Pressure = 
clinic sBP + (33.57419 + (0.6269306 * age) + (-3.598565 * male sex) + (-0.036267 * 
clinic sBP) + (0.3617946 * sBP change) + (-0.2093273 * BMI) + (-5.069816 * diagnosis 
of hypertension) + (0.175593 * duration of hypertension) + (6.942526 * 
antihypertensive prescription) + (-0.6181946 * pulse pressure) + (-0.0077222 * (age * 
clinic sBP)) + (0.009603 * (age * pulse pressure)) + (0.2976424 * (sex * BMI)) + (-
0.2587568 * (sex * duration of hypertension)) + (-14.73537 * (sex * antihypertensive 
prescription)) + (13.3899 * (sex * diagnosis of hypertension))) 
sBP = systolic blood pressure, binary variables coded as yes or no. 
Proof-BP has recently been proposed and validated as an estimate for daytime ABPM.18 
A daytime ABPM value of 135/85 mmHg is equivalent to a clinic value of 140/80 mmHg; 
therefore, when comparing the two blood pressure techniques a Proof-BP systolic value of ≥ 135 
mmHg will be considered hypertensive at the 140 mmHg threshold level.17 
Separate analyses for both the JNC8 definition, which classifies hypertension as 140/90 
mmHg, and the AHA/AAC definition (130/80 mmHg), were conducted using the systolic blood 
pressure level only. Subjects are classified as either hypertensive or not hypertensive in a binary 
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fashion. Additionally, the goal was to identify sensitivity, specificity and predictive values 
between Clinic BP and Proof-BP for the outcomes of MI, stroke, and CHF.  
In addition, because the combined use of Clinic BP and Proof-BP offers a means to 
estimate both WCH and MH these forms of hypertension were also calculated for the overall 
split population.   
Statistical analysis 
 Data presented are either binary or continuous. Binary data is Yes/No and is presented as 
number of Yeses with the percent of total in parenthesis. Continuous data is presented as means 
± standard deviation. To detect significant differences between groups, Chi-Square was 
performed on binary variables and t-test was performed on continuous variables. These results 
were reported as a p-value, or, for the outcomes, prevalence odds ratios (POR). An alpha value 
of ≤0.05 was considered significant. Multivariate logistic regression models were constructed for 
each outcome to control for characteristics that were significantly different between the two 
groups. The results from these models were reported as adjusted POR. Sensitivity, specificity, 




Figure 1 – Eligibility and randomization. Out of 9,971 participants, 821 were assigned to Clinic BP and 822 to Proof-BP. 
Results 
Baseline characteristics for the 1,643 participants are presented in Table 1. The sample 
was split equally with no significant differences in characteristics of interest observed between 
the two groups. The prevalence of MI, stroke, and CHF is 7.9%, 5.9%, and 6.6%, respectively. 
The average age is 65.3 ± 6.7 years old and 49.2% are male. 55.4% of the sample have been told 
by a doctor they have hypertension of whom 92.6% report using antihypertensive medications.  
Table 1- Baseline characteristics of the study population 










• Mean age in years (SD) 65.3 (6.7) 65.1 (6.5) 65.6 (6.9) .1713 
• Male (%) 809 (49.2) 403 (49.1) 406 (49.4) .9015 
• Race (%)     
o Non-Hispanic White 557 (33.9) 269 (32.8) 288 (35.0) .3308 
o Black 343 (20.9) 175 (21.3) 168 (20.4) .6617 
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o Hispanic 556 (33.8) 293 (35.7) 263 (32.0) .1137 
o Other 187 (11.4) 84 (10.2) 103 (12.5) .1423 
• Education (%)     
o Less than HS 462 (28.1) 237 (28.9) 225 (27.4)  .5004 
o HS graduate or GED 358 (21.8) 175 (21.3) 183 (22.3) .6419 
o Some College 454 (27.6) 222 (27.0) 232 (28.2) .5916 
o College Graduate 368 (22.4) 187 (22.8) 181 (22.0) .7126 
     
• Previous Cardiovascular Event 
(%) 
    
o MI 130 (7.9) 61 (7.4) 69 (8.4) .4691 
o Stroke 97 (5.9) 42 (5.1) 55 (6.7) .1756 
o CHF 109 (6.6) 55 (6.7) 54 (6.6) .9158 
     
• Ever Told You Had Diabetes (%) 429 (26.1) 223 (28.1) 206 (26.2) .4016 
• Cigarette-smoking status (%)     
o Current Smoker 302 (18.4) 151 (18.4) 151 (18.4) .9907 
o Former Smoker 544 (33.1) 278 (33.9) 266 (32.4) .5180 
o Never Smoker 794 (48.3) 390 (47.5) 404 (49.2) .5046 
• Mean BMI (SD) 29.9 (6.5) 29.6 (6.2) 30.1 (6.7) .1284 
• Clinic Blood Pressure (SD)     
o Systolic 133 (19) 133 (19) 133 (19) .6589 
o Diastolic 70 (12) 69 (12) 70 (12) .6598 
• Proof-BP (SD)     
o Systolic 133 (10)  133 (10) 133 (10) .7600 
o Diastolic 72 (7) 72 (7) 72 (7) .7210 
• Ever Told You Had Hypertension 
(%) 
910 (55.4) 454 (55.3) 456 (55.5) .9428 
o Age Told You Had 
Hypertension (SD) 
51.4 (11.8) 51.1 (11.2) 51.6 (12.3) .4881 
• Currently on Antihypertensives 
(%) 
843 (51.3) 420 (92.5) 423 (92.8) .8842 
• Ever Told You High Cholesterol 
(%) 
903 (55.0) 450 (55.6) 453 (55.4) .9429 
• Currently on Cholesterol 
Lowering Medications (%) 
638 (38.8) 315 (79.8) 323 (79.4) .8923 
SD=standard deviation. Parenthesis for binary variables indicate column percentage, and parenthesis for continuous variables 
indicate standard deviation. There were no significant differences at the p≤0.05 level between the two groups. Race was self-
reported. Hispanic includes Mexican American and “Other Hispanic”. Other includes Asian and multiracial persons. History of 
previous cardiovascular event, “Ever told you had high blood pressure”, and “Ever told you had high cholesterol”, were counted 
if the participant was ever told by a doctor to have had one of these.  
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The average Clinic BP value is 133 ± 19/69 ± 12 mmHg and the average Proof-BP value 
is 133± 10/72 ± 7 mmHg. As highlighted in Figure 2 the standard deviation for the systolic blood 
pressure of Proof-BP (10 mmHg) is dramatically smaller than that of Clinic BP at 19 mmHg (F-
statistic = 1.98, p <0.001). Among the whole sample, the range of the systolic values for Clinic 
BP is 146 mmHg while that of Proof-BP is 74 mmHg. The Clinic BP was found to be associated 
with Proof-BP with an R-Squared = 0.8318 and p < 0.0001 in the overall population data.
 
Figure 2- The systolic blood pressure of Proof-BP (red) and Clinic BP (black). Proof-BP has a much smaller standard deviation 
than Clinic BP (F-stastic 1.98, p<0.001). 
 Despite the increased precision of the blood pressure assessment at both blood pressure 
thresholds, Proof-BP was determined to classify more participants as hypertensive – see Figure 
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4. For example, at the 140 mmHg level, Proof-BP classifies 37.2% as hypertensive versus the 
32.4% in the Clinic BP group. This trend remains at the 130 mmHg level with Proof-BP 
classifying 60.0% as hypertensive and Clinic BP classifying only 52.7%. Factoring in WCH and 
MH, the prevalence of WCH increased the prevalence of hypertension in the population assigned 
to Clinic BP by 11.3% at the 140 mmHg threshold and 9.8% at the 130 mmHg threshold. In 
contrast, the inclusion of masked hypertension as part of the Proof-BP estimate increased the 
prevalence of hypertension by 24.2% and 18.6%, respectively.  
Hispanics were found to be most likely to have WCH representing 35.6% and 35.9% of 
those with the condition in the 140 mmHg and 130 mmHg groups, respectively. Whites were 
found to be most likely to have MH representing 36.7% and 42.4% of those with the condition in 
the 140 mmHg and 130 mmHg groups, respectively.  
 
Figure 3- Demonstrates the total number of hypertensives at all levels, as well as the number of WCH or MH that contribute to 
the total.  
Table 2 presents the split population data for Clinic BP compared to Proof-BP at both 
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was 65.9 ± 6.6 years old compared to 67.7 ± 7.1 for the Proof-BP group (p = .0023). Proof-BP 
identified a higher percent of white race (32.0% vs. 22.9%) and other race (14.7% vs. 9.0%) as 
hypertensive. Clinic BP identified a higher percent of Hispanic race (39.1% vs. 31.1%) as 
hypertensive as well as a higher clinic systolic blood pressure (154 ± 14 mmHg vs. 151 ±17 
mmHg) overall. For the 130 mmHg threshold, the average age of the Clinic BP group was 65.6 ± 
6.5 years old compared to 67.3 ± 6.8 for the Proof-BP group (p = .0001). Similar to the 140 
mmHg threshold, at this 130 mmHg level, Proof-BP identify a higher percent of white race 
(33.4% vs. 26.7%), while Clinic BP identify a higher percent of Hispanic race (38.6% vs. 31.8%) 
and a higher clinic systolic blood pressure (146 ± 15 mmHg vs.144 ± 17 mmHg).  
The prevalence of any of the three CV outcomes at 140 mmHg is 20.3% for Clinic BP 
and 26.5% for Proof-BP. At the 130 mmHg level, the prevalence for CV outcomes is 19.6% for 
Clinic BP and 24.3% for Proof-BP. Table 3 shows the outcomes MI, stroke, and CHF by blood 
pressure assessment strategy, of which none of the crude odds ratios are significant. To examine 
whether significant differences in the characteristics observed in Table 2 influence the 
interpretation for cardiovascular outcomes, a logistic regression model was built for each 
outcome and stepwise elimination was performed. Table 4 shows the characteristics that were 
found to be significant for each outcome along with their Odds Ratios. For example, at 140 
mmHg the crude OR for CHF is 1.28 (0.68 – 2.39) and after controlling for characteristics in 
Table 2, the adjusted OR is 1.15 (0.61 – 2.16) with Age being the sole significant characteristic 
with an OR of 1.06 (1.01 – 1.11). Other outcomes at the 140 mmHg level are MI and Stroke. For 
MI, Age, Hispanic race, and systolic clinic blood pressure were found to be significant. 
Compared to Clinic BP, the OR for Age is 1.08 (1.03-1.13), Hispanic race is 1.93 (1.05-3.53), 
and systolic clinic blood pressure is 1.02 (1.00-1.04). For CHF, Age was significant with an OR 
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of 1.06 (1.01-1.11). In the 130 mmHg group, for MI, Age was significant with an OR of 1.08 
(1.04-1.13). For CHF, Age was also significant with an OR of 1.07 (1.03-1.11). Stroke was not 
found to be associated with any characteristics in either group. Therefore, while there were 
factors that independently contributed to the risk of the CV outcomes based on blood pressure 
strategy, adjustments did not impact the overall population interpretation.  





































• Race (%)       










o Hispanic 104 
(39.1) 





o Other 24 (9.0) 45 (14.7) .0374* 39 (8.9) 59 (12.2) .1083 
• Education (%)       







o HS graduate or GED 53 (19.9) 67 (21.9) .5637 85 (19.4) 113 
(23.3) 
.1503 





o College Graduate 60 (22.6) 50 (16.3) .0599 89 (20.3) 91 (18.8) .5511 
• Previous Cardiovascular Event 
(%) 
      
o MI 21 (7.9) 28 (9.2) .5925 32 (7.3) 41 (8.5) .5188 
o Stroke 15 (5.6) 27 (8.8) .1453 25 (5.7) 39 (8.0) .1635 
o CHF 18 (6.8) 26 (8.5) .4387 29 (6.6) 38 (7.8) .4778 
o Composite 44 (16.5) 58 (19.0) .4521 70 (16.0) 84 (17.3) .5862 





• Cigarette-smoking status (%)       
o Current Smoker 48 (18.1) 48 (15.7) .4515 76 (17.4) 81 (16.7) .7928 
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• WCH (%) 30 (11.3) - - 43 (9.8) - - 
• MH (%) - 74 (24.2) - - 90 (18.6) - 
• Clinic Blood Pressure (SD)       
o Systolic 154 (14) 151 (17) .0205* 146 (15) 144 (17) .0151* 
o Diastolic 74 (13) 72 (13) .1665 72 (13) 71 (13) .1202 
• Proof-BP (SD)       
o Systolic 143 (7) 143 (7) .7841 139 (8) 139 (8) .8267 
o Diastolic 73 (8) 72 (8) .1435 73 (7) 72 (8) .1147 












































o Currently on Cholesterol 










SD=standard deviation. Parenthesis for binary variables indicate column percentage, and parenthesis for continuous variables 
indicate standard deviation. Race was self-reported. Hispanic includes Mexican American and “Other Hispanic”. Other includes 
Asian and multiracial persons. History of previous cardiovascular event, “Ever told you had high blood pressure”, and “Ever told 



















































































































Table 4 – This table displays the characteristics for each outcome that remain significant at the 0.05 level after stepwise 
elimination  
140 mmHg   
Previous CV Event Significant 
Characteristic 
Odds Ratio 
MI Age 1.08 (1.03-1.13) 




Stroke - - 
CHF Age 1.06 (1.01-1.11) 
130 mmHg   
Previous CV Event Significant 
Characteristic 
Odds Ratio 
MI Age 1.08 (1.04-1.13) 
Stroke - - 
CHF Age 1.07 (1.03-1.11) 
Age, Hispanic race, and systolic clinic blood pressure are significant for MI at 140 mmHg. Age remains significant for most of the 
outcomes. 
Figure 4 shows a graph of the prevalence for each cardiovascular outcome as a 
consequence of lowering the systolic blood pressure threshold from 140 mmHg to 130 mmHg in 
both the Clinic BP and the Proof-BP strategies for examining hypertension. Notably, the within 
strategy comparisons show no difference in prevalence with either blood pressure assessment 
approach. The following are the p-values: Clinic BP MI = .7741, Clinic BP Stroke = .9696, 




Figure 4- prevalence of each cardiovascular outcome for both measurement techniques and at each blood pressure threshold. 
 
Table 5 shows the sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) for Clinic BP and Proof -BP. The sensitivity of both Clinic BP and 
Proof-BP are low for this representative, versus clinical-based population; however, the 
specificity and NPV are much higher. At the 140 mmHg threshold, the specificity is greater for 
Proof-BP at 80% while only approximately 68% for Clinic BP. As expected, at 130 mmHg the 
sensitivity increases to between 53.1% and 61.9% with a fall in specificity for both assessments 
with a value of approximately 47% for Clinic BP and 42% for Proof-BP. Due to the low overall 
prevalence of the cardiovascular outcomes in this NHANES population, as expected the PPV is 
low. The NPV at both blood pressure thresholds range from 91.9 to 95.7 with minimal difference 
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Table 5- Sensitivity, specificity, and predictive values. 
At 140 mmHg 








• Myocardial Infarction      
o Proof-BP 26.1 80.4 10.3 92.7 
o Clinic BP 30.8 67.8 7.6 91.9 
• Stroke     
o Proof-BP 26.8 80.3 7.9 94.6 
o Clinic BP 40.2 68.4 7.5 94.8 
• CHF     
o Proof-BP 27.5 80.4 9.1 94.0 
o Clinic BP 36.7 68.3 7.6 93.8 
At 130 mmHg 
    
• Myocardial Infarction     
o Proof-BP 64.6 42.0 8.7 93.2 
o Clinic BP 53.1 47.2 7.9 92.1 
• Stroke     
o Proof-BP 70.1 42.2 7.1 95.7 
o Clinic BP 61.9 47.7 6.9 95.2 
• CHF     
o Proof-BP 66.1 42.0 7.5 94.6 
o Clinic BP 57.8 47.5 7.3 94.1 
As expected, sensitivity increases while specificity decreases when lowering the threshold. NPV is approximately equally strong 
between both measurement techniques.  
Discussion 
There is no question that hypertension ranks as one of the world’s most preventable 
causes of premature mortality.3 In 2009, high blood pressure was either the primary or 
contributing cause of death for nearly 350,000 Americans.29 This represented almost 15% of all 
US deaths.29 Hypertension increases the risk of stroke, MI, and CHF.8 Permanent impairment 
from stroke is one of the most common causes of long-term disability in America.22 The 
morbidity of MI is also significant with 800,000 Americans suffering from a heart attack each 
year. It is estimated that 70% of first MIs can be at least partially attributed to hypertension.21   
25 
 
Furthermore, the prevalence of CHF has been growing due to increases in lifespans and currently 
cost the United States over $39 billion per year.30, 31 The morbidity and mortality of these 
conditions creates enormous financial implications, but more importantly they are the cause of 
substantial years of life lost. 
Due to the many factors that can influence one’s blood pressure, hypertension is difficult 
to diagnose. Some of these factors, such as the time of day of the measurement, can be made 
consistent across a population while others, such as medications, may be more difficult to 
control. These many influences create a large range of blood pressure measurements as can be 
seen in Figure 2. The question then becomes, “How do we determine which of these 
measurements represent clinically relevant hypertension and which can be thought of as 
artificially elevated or depressed?”. The findings here provide a clear indication that using Proof-
BP improves the estimate of blood pressure which would be valuable in clinical practice. 
 As a tool, Proof-BP was developed as a means to estimate a patient’s ABPM that was 
less time and resource intensive than traditional 24-hour monitoring.18 It has been identified to 
accurately classify blood pressure status in 93% of patients within a primary care setting when 
compared to ABPM.18 What has not been studied is the precision for which Proof-BP estimates 
blood pressure compared to a single clinic measurement and how this influences its sensitivity, 
specificity, and predictive values. This thesis found that Proof-BP provides a significantly 
narrower standard deviation in its estimate of systolic blood pressure than Clinic BP. 
Importantly, this improved estimate also increases the specificity of Proof-BP at the 140 mmHg 
level to 80% for MI, Stroke, and CHF. This makes Proof-BP a more effective method for ruling 
out cardiovascular disease as it will result in fewer false positives compared to Clinic BP. This 
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could provide value to clinicians in an outpatient setting where screening many patients using 
ABPM is not feasible. However, it is important to note that the specificity decreases dramatically 
at the 130 mmHg threshold. While this level classifies more individuals as hypertensive and will 
increase sensitivity, it will also decrease specificity making it more difficult to rule out 
cardiovascular disease. The NPV of both techniques remains high at both thresholds making 
them equally viable for ensuring those who screen negative do not have the disease. 
Another advantage clearly realized in this thesis project is that Proof-BP allows for the 
opportunity to diagnose both WCH and MH, which normally requires ABPM. In this NHANES 
sample, Proof-BP classified more individuals as hypertensive compared to Clinic BP (306 vs. 
266 at 140 mmHg, 485 vs. 438 at 130 mmHg). This difference can largely be explained by the 
high prevalence of MH (24.2% and 18.6% at 140 mmHg and 130 mmHg, respectively) in the 
Proof-BP assessment. MH cannot be detected with a single blood pressure. In fact, the 
individuals classified as MH would be considered normotensive under the traditional clinical 
blood pressure assessment. Additionally, comparing the blood pressure assessment groups, 
Proof-BP detects a higher prevalence for every cardiovascular outcome. While these differences 
are not statistically significant, we believe this difference could be magnified in a population 
with higher levels of MH. MH is an important disease to diagnose because it is thought to 
increase one’s cardiovascular risk. In a 3 year prospective cohort study by Bobrie et al. of 
patients at least 60 years old, the authors found the hazard ratio of cardiovascular events was 
2.06 (95% CI 1.22-3.47) when comparing masked hypertensives to controlled hypertensives.32 
Furthermore, because Proof-BP dramatically improves the standard deviation of the blood 
pressure measurement, it makes for a valuable tool in diagnosing WCH.  
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In those with WCH the Clinic BP will be elevated compared to their ambulatory blood 
pressure. Relying on Proof-BP in this scenario could prevent individuals with WCH from being 
prescribed antihypertensives which may not be needed. A meta-analysis by Briasoulis et al. 
found significantly fewer cardiovascular events in patients with WCH when compared to patients 
with sustained hypertension (OR 0.40, 95% CI 0.32-0.51; P<0.001).24  However, the same study 
showed significantly more cardiovascular events in patients with WCH compared to 
normotensives (OR 1.73, 95% CI 1.27-2.36; P=0.006)24. Currently, there are no widely agreed 
upon guidelines for treating WCH, so the decision to medicate or not can be left between the 
clinician and patient.  
The high prevalence of WCH and MH means relying on a single in-clinic measurement is 
unreliable for a significant number of patients. In our sample, the number of hypertensive 
individuals with WCH was 11.3% and 9.8% at the 140 mmHg and 130 mmHg levels, 
respectively. Numerous international studies have placed the prevalence between 10.4% and 
52.9%.33 A US study published in 2017, and based on a nationally representative sample, 
suggested that 20% of hypertensive patients actually have WCH.34 The prevalence in this thesis 
is somewhat lower than most estimates likely due to the upper age cutoff of 79 years old and to 
the relative high level of blood pressure control along with a very high antihypertensive usage. In 
this sample, the prevalence of MH is 24.2% and 18.6% at the 140 mmHg and 130 mmHg levels, 
respectively. These findings are in agreement with those from a systematic review using 
prospective cohort studies with individuals from the general population published in 2014 that 
suggested approximately 15 -30% of adults who do not have elevated clinic blood pressure have 
the condition.35, 36 The etiologies behind either of these conditions is complex and not fully 
understood; however, individual factors such as gender, BMI, race, and cardiovascular disease 
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appear to influence their occurrence.18 The use of Proof-BP for epidemiological studies would 
allow access to these otherwise missed forms of hypertension, thereby help improve our 
understanding of their associated risk profiles. 
Racial differences were found between the two blood pressure measurement techniques. 
For example, White and Hispanic race were identified as significantly different at both the 140 
mmHg and 130 mmHg levels. While the split populations were similar for characteristics, Proof-
BP captured more Whites while Clinic BP captured more Hispanics. As an estimate of ABPM, 
Proof-BP is heavily influenced by MH while Clinic BP is influenced by WCH. This pattern 
suggest that Whites have higher levels of MH while Hispanics have higher levels of WCH. The 
published literature supports the notion that there are racial differences and that Whites are more 
likely to have MH than Hispanics. 34, 35 However, the prevalence of WCH among racial groups is 
less clear. One study suggested that Whites are more likely to have WCH than Hispanics.37 It is 
unclear why the opposite pattern was seen in this thesis’s WCH group. 
The logistic modeling of the data suggests that after controlling for the significant 
characteristics, there remained characteristics, such as age, that were found to influence the 
distribution of participants between the two measurement techniques. For MI and CHF in both 
groups, age was found to be more significantly associated with Proof-BP than Clinic BP. Every 
year older is associated with an OR between 1.06-1.08 for these outcomes. One explanation for 
this is the fact that Proof-BP assigns weight to not only age, but also to factors such as duration 
of hypertension, systolic variability, and pulse pressure. All three are likely to increase with age 
so the older an individual is, the more variables they are likely to have that will increase their 
Proof-BP value. 38, 39 The logistic modeling also shows that at the 140 mmHg level, Proof-BP is 
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a better indicator of previous MI in Hispanics than in the other races. The odds of having ever 
experienced a heart attack are 1.93 times greater for Hispanics in the Proof-BP group compared 
to Hispanics in the Clinic BP group. While, it is unclear why this may be the case, it is possible 
that Hispanics who have had an MI have greater Proof-BP values than other races. Perhaps 
Hispanics in this sample are older, have a higher prevalence of males, have a greater BMI, or are 
different from other racial groups in any of the other variable that affects Proof-BP. Relying on a 
single clinic blood pressure would likely stratify older Hispanic patients as being lower risk than 
they are. More research is needed, but these findings highlight that Proof-BP may be an 
important clinical tool for use in older Hispanic populations.  
Chronic high blood pressure is thought to increase MI, stroke, and CHF risk through 
several mechanisms. Mainly, elevated blood pressure increases the amount of sheer stress of the 
endothelial lining of blood vessels leading to atherosclerosis and plaque formation.22, 40 Most 
MIs and strokes are the result of a ruptured atherosclerotic plaque that occludes a coronary or 
cerebral artery leading to the death of downstream tissue.22, 40  
Interestingly, decreasing the threshold from 140 mmHg to 130 mmHg was not associated 
with a greater prevalence of CV outcomes. As mentioned previously, lowering the target has 
been controversial with many health agencies publicly criticizing the change.2, 41, 42 Some argue 
that lowering blood pressure targets by 10 mmHg has a poor risk-benefit profile. Because it 
classifies nearly 50% of American adults as hypertensive, they claim the “one size fits all” 
approach may not be appropriate given the vast spectrum of age and health statuses in the 
patients who would be subject to these new guidelines.41 On the other hand, the ACA/AHA back 
their recommendation with evidence that hypertension causes more CV deaths than any other 
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modifiable risk factor and lowering blood pressure to below <130 mmHg results in fewer CV 
events as seen in the SPRINT trial.17, 43 Results of the SPRINT trial found significantly lower 
cardiovascular events for intensive blood pressure management (SBP < 120 mmHg) versus 
routine management (SBS < 140 mmHg) in patients with high cardiovascular disease risk but 
without a history of diabetes, stroke, or heart failure.44 This is in contrast to the ACCORD trial 
which enrolled patients with type 2 diabetes and found that lowering systolic blood pressure to 
<120 mmHg did not reduce the rates of cardiovascular events compared to systolic BP of < 140 
mmHg.45 In our sample, lowering the threshold classified 172 additional individuals as 
hypertensive via Clinic BP and 179 additional via Proof-BP without detecting a greater 
prevalence of CV events. These results are more in line with the results of the ACCORD trial in 
that they do not support lowering the diagnostic threshold for hypertension. 
A recent study compared the cardiovascular outcomes between NHANES participants 
and those in the SPRINT and ACCORD trials at different hypertensive thresholds. The authors 
found that lowering the diagnostic threshold to 130/80 mmHg would reclassify 24 million 
individuals as hypertensive while recommending that 4.3 million start antihypertensives.46 The 
study found that these newly diagnosed hypertensives were younger, had fewer comorbidities, 
and had a lower 10-year atherosclerotic cardiovascular disease (ASCVD) risk than the 
participants in either the SPRINT or ACCORD trials.46 Furthermore, participants in the SPRINT 
and ACCORD trials who were not on baseline antihypertensives had significantly fewer 
cardiovascular events than those on antihypertensive at baseline.46 This suggests that treating 
those at highest cardiovascular risk would be most beneficial, while medicating low-risk 
individuals would be marginally valuable. 
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 This thesis has several limitations. It must be recognized that NHANES data is cross-
sectional and cannot establish a temporal relationship between blood pressure and the outcomes. 
Importantly, the cardiovascular outcomes occurred without mortality. Hypertension here focused 
on systolic hypertension and did not take into consideration participants diastolic blood pressure. 
This was because the Proof-BP calculation for diastolic blood pressure required variables not 
included in the NHANES dataset. Isolated diastolic hypertension (IDH) affects 6.5% of 
Americans when using the ACC/AHA criteria, and 3.9% when using JNC 8 criteria.47, 48 
However, it is believed that IDH does not carry a significantly increased cardiovascular risk 
when compared to normotensives.48, 49 Furthermore, much of the NHANES data is self-reported. 
For example, participants were asked about their medical history. With self-reported data, 
inaccuracies are expected and dependent on participant honesty, question interpretation, and 
response bias. Additionally, NHANES participants are relatively healthy and Proof-BP was 
derived from a primary care setting. These results should not be generalized to individuals 
considered high-risk. 
 In conclusion, Proof-BP is a valuable tool that can be used in a primary care setting to 
capture not only sustained hypertension but also WCH and MH. Importantly, Proof-BP offers a 
simple clinical and epidemiological tool to assess these particular forms of hypertension that are 
otherwise missed with traditional assessment. Proof-BP had high specificity at the 140 mmHg 
systolic blood pressure threshold as well as high NPV for both thresholds. These findings 
indicate that Proof-BP helps to rule out individuals without MI, stroke, or CHF history. It can 
likely provide a valuable alternative to the resource intensive 24-hour ABPM. While simpler for 
all patients, using one clinical encounter is beneficial for improved health equity. This thesis 
provides some evidence that Proof-BP may be superior to Clinic BP in assessing CV prevalence 
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for certain groups, for example in the Hispanic subpopulation, but a prospective study is needed 
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